Our current focus is on Phase II clinical trial of PRI-002, a synthetic all-D-peptide for causal treatment of Alzheimer’s disease.
Thus, PRI-002 has three unique selling propositions (USPs):
New mechanism of action
Specific elimination of toxic Aβ oligomers
New drug substance class
Oral drug administration
Priavoid follows a completely new strategy for treatment of Alzheimer’s disease.
We have developed stable D-peptides that are able to overcome the blood-brain barrier, do not interfere with formation or clearance with normal non-toxic Abeta monomers, but specifically eliminate cytotoxic Abeta oligomers.